BCL2 and B-cell chronic lymphocytic leukemia: As a druggable target, the first Bcl-2 inhibitor venetoclax was approved by FDA in 2016 for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) in adults [49].